ALK and non-small cell lung carcinoma: In recent years, targeted therapy with small molecular tyrosine kinase inhibitors targeting the EGFR/ALK/ROS1, and immunotherapy blocking immune checkpoints have been approved to treat patients with nonsmall cell lung cancer (NSCLC), and of note, the overall survival and quality-of-life have been drastically improved (2, 3).